{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:24:00Z","timestamp":1789025040858,"version":"build-2803163510"},"reference-count":123,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004040","name":"Catholic University of Leuven","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","gastrojournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1053\/j.gastro.2023.11.307","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T23:43:10Z","timestamp":1706830990000},"page":"572-587.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Patient-Reported Outcomes in Disorders of Gut\u2013Brain Interaction"],"prefix":"10.1053","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3206-6704","authenticated-orcid":false,"given":"Jan","family":"Tack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florencia","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian E.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2023.11.307_bib1","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2016.02.032","article-title":"Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV","volume":"148","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1053\/j.gastro.2023.11.307_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14019","article-title":"Combining symptoms and biomarkers: the future diagnostic approach for disorders of gut-brain interaction?","volume":"32","author":"Simr\u00e9n","year":"2020","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2023.11.307_bib3","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/ajg.2011.201","article-title":"Severity in irritable bowel syndrome: a Rome Foundation Working Team report","volume":"106","author":"Drossman","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib4","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1053\/j.gastro.2021.07.037","article-title":"A\u00a0review of the evidence and recommendations on communication skills and the patient-provider relationship: a Rome Foundation Working Team report","volume":"161","author":"Drossman","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.11.307_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11136-007-9295-0","article-title":"The impact of measuring patient-reported outcomes in clinical practice: a systematic review of the literature","volume":"17","author":"Valderas","year":"2008","journal-title":"Qual Life Res"},{"key":"10.1053\/j.gastro.2023.11.307_bib6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11136-019-02320-8","article-title":"Capturing the patient voice: implementing patient-reported outcomes across the health system","volume":"29","author":"Austin","year":"2020","journal-title":"Qual Life Res"},{"key":"10.1053\/j.gastro.2023.11.307_bib7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1200\/EDBK_200383","article-title":"Implementation of patient-reported outcomes in routine medical care","volume":"38","author":"Basch","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1053\/j.gastro.2023.11.307_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-4-79","volume":"4","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"10.1053\/j.gastro.2023.11.307_bib9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/ajg.2010.12","article-title":"Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design","volume":"105","author":"Trentacosti","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib10","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1365-2036.2010.04464.x","article-title":"Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials","volume":"32","author":"Spiegel","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.11.307_bib11","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3109\/00365521.2012.712999","article-title":"Systematic review: symptom assessment using patient-reported outcomes in gastroesophageal reflux disease and dyspepsia","volume":"47","author":"Chassany","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib12","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1053\/j.gastro.2005.11.059","article-title":"Functional gastroduodenal disorders","volume":"130","author":"Tack","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.11.307_bib13","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1053\/j.gastro.2016.02.011","article-title":"Functional gastroduodenal disorders","volume":"150","author":"Stanghellini","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.11.307_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(08)60663-0","article-title":"Influence of PPI run-in, pH monitoring and nutrient tolerance on efficacy outcomes of acotiamide hydrochloride (YM443), a novel acetylcholine esterase inhibitor, in functional dyspepsia","volume":"134","author":"Tack","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.11.307_bib15","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.14309\/ajg.0000000000000619","article-title":"Gastroesophageal reflux disease-functional dyspepsia overlap: do birds of a feather flock together?","volume":"115","author":"Geeraerts","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib16","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2036.2010.04566.x","article-title":"Review article: endpoints used in functional dyspepsia drug therapy trials","volume":"33","author":"Ang","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.11.307_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01535722","article-title":"GSRS\u2014a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease","volume":"33","author":"Svedlund","year":"1988","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2023.11.307_bib18","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s11136-004-9567-x","article-title":"Development and psychometric evaluation of the Patient Assessment of Upper Gastrointestinal Symptom Severity Index (PAGI-SYM) in patients with upper gastrointestinal disorders","volume":"13","author":"Rentz","year":"2004","journal-title":"Qual Life Res"},{"key":"10.1053\/j.gastro.2023.11.307_bib19","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s10620-017-4599-6","article-title":"The validity of a new Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) for evaluating symptoms in the clinical setting","volume":"62","author":"Koloski","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2023.11.307_bib20","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1007\/s10620-015-3647-3","article-title":"Multi-dimensional gastrointestinal symptom severity index: validation of a brief GI symptom assessment tool","volume":"60","author":"Crowell","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2023.11.307_bib21","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/jgh.14937","article-title":"A\u00a0symptom severity questionnaire for patients suffering from functional gastrointestinal disorder: FGI-Checklist","volume":"35","author":"Chan","year":"2020","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.11.307_bib22","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/00042737-199610000-00006","article-title":"The Glasgow Dyspepsia Severity Score \u2013 a tool for the global measurement of dyspepsia","volume":"8","author":"El-Omar","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.11.307_bib23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/0895-4356(95)00584-6","article-title":"Developing a condition-specific measure of health for patients with dyspepsia and ulcer-related symptoms","volume":"49","author":"Garratt","year":"1996","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1053\/j.gastro.2023.11.307_bib24","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1046\/j.1365-2036.1998.00399.x","article-title":"Development of a digestive health status instrument: tests of scaling assumptions, structure and reliability in a primary care population","volume":"12","author":"Shaw","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.11.307_bib25","first-page":"1257","article-title":"The Leeds Dyspepsia Questionnaire: a valid tool for measuring the presence and severity of dyspepsia","volume":"12","author":"Moayyedi","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2036.2006.03233.x","article-title":"The Short-Form Leeds Dyspepsia Questionnaire validation study","volume":"25","author":"Fraser","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.11.307_bib27","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1007\/s10620-004-9578-z","article-title":"Development and validation of a cross cultural questionnaire to evaluate nonulcer dyspepsia: the Porto Alegre Dyspeptic Symptoms Questionnaire (PADYQ)","volume":"49","author":"Sander","year":"2004","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2023.11.307_bib28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2036.1999.00445.x","article-title":"Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index","volume":"13","author":"Talley","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.11.307_bib29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1440-1746.2002.02713.x","article-title":"The Hong Kong index of dyspepsia: a validated symptom severity questionnaire for patients with dyspepsia","volume":"17","author":"Hu","year":"2002","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.11.307_bib30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1572-0241.2002.05419.x","article-title":"Reliability, validity, and responsiveness of Severity of Dyspepsia Assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy","volume":"97","author":"Rabeneck","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib31","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1023\/A:1005558204440","article-title":"Patient-based assessment in dyspepsia - development and validation of Dyspepsia Symptom Severity Index (DSSI)","volume":"45","author":"Leidy","year":"2000","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2023.11.307_bib32","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/nmo.12381","article-title":"Functional dyspepsia: outcome of focus groups for the development of a questionnaire for symptom assessment in patients suffering from postprandial distress syndrome (PDS)","volume":"26","author":"Carbone","year":"2014","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2023.11.307_bib33","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/apt.13753","article-title":"Validation of the Leuven Postprandial Distress Scale, a questionnaire for symptom assessment in the functional dyspepsia\/postprandial distress syndrome","volume":"44","author":"Carbone","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"113","key":"10.1053\/j.gastro.2023.11.307_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/ajg.2017.265","article-title":"Development of a symptom-focused patient- reported outcome measure for functional dyspepsia: the Functional Dyspepsia Symptom Diary (FDSD)","volume":"460","author":"Taylor","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1053\/j.gastro.2023.11.307_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13496","article-title":"Development of a real-time patient-reported outcome measure for symptom assessment in patients with functional dyspepsia using the experience sampling method","volume":"31","author":"Smeets","year":"2019","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2023.11.307_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.695809","article-title":"Developing a scale for the evaluation of people with post-prandial distress syndrome","volume":"9","author":"Xiao","year":"2021","journal-title":"Front Public Health"},{"key":"10.1053\/j.gastro.2023.11.307_bib37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5056\/jnm20250","article-title":"Development and validity assessment of a self evaluation questionnaire for functional dyspepsia: a multicenter prospective study in Korea","volume":"28","author":"Jung","year":"2022","journal-title":"J\u00a0Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2023.11.307_bib38","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/00005650-198807000-00007","article-title":"The MOS short-form general health survey. Reliability and validity in a patient population","volume":"26","author":"Stewart","year":"1988","journal-title":"Med Care"},{"key":"10.1053\/j.gastro.2023.11.307_bib39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"10.1053\/j.gastro.2023.11.307_bib40","first-page":"41","article-title":"Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD)","volume":"583","author":"Wiklund","year":"1998","journal-title":"Eur J Surg"},{"key":"10.1053\/j.gastro.2023.11.307_bib41","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S1542-3565(04)00349-0","article-title":"Responsiveness and interpretation of a quality of life questionnaire specific to upper gastrointestinal disorders","volume":"2","author":"De La Loge","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.11.307_bib42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1046\/j.1365-2036.2001.00900.x","article-title":"Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form","volume":"15","author":"Talley","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1053\/j.gastro.2023.11.307_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13284","article-title":"Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial","volume":"30","author":"Tack","year":"2018","journal-title":"Neurogastroenterol Motil"},{"issue":"2","key":"10.1053\/j.gastro.2023.11.307_bib44","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13739","article-title":"The effect of rikkunshito on gastrointestinal symptoms and gastric motor function: the first study in a Belgian functional dyspepsia population","volume":"32","author":"Masuy","year":"2020","journal-title":"Neurogastroenterol Motil"},{"issue":"8","key":"10.1053\/j.gastro.2023.11.307_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14337","article-title":"A\u00a0double-blind randomized, multicenter, placebo-controlled study of itopride in functional dyspepsia postprandial distress syndrome","volume":"34","author":"Carbone","year":"2022","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2023.11.307_bib46","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S2468-1253(21)00226-0","article-title":"Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial","volume":"6","author":"Wauters","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.11.307_bib48","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1136\/gutjnl-2011-301454","article-title":"A\u00a0placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia","volume":"61","author":"Matsueda","year":"2012","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2023.11.307_bib49","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7326\/0003-4819-111-8-671","article-title":"A\u00a0patient questionnaire to identify bowel disease","volume":"111","author":"Talley","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2023.11.307_bib50","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/BF02064187","article-title":"Functional bowel disorders. A multicenter comparison of health status and development of illness severity index","volume":"40","author":"Drossman","year":"1995","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2023.11.307_bib51","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","article-title":"The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress","volume":"11","author":"Francis","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.11.307_bib52","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365529709011203","article-title":"Stool form scale as a useful guide to intestinal transit time","volume":"32","author":"Lewis","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib53","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-230X-8-30","article-title":"Evaluation of the Birmingham IBS symptom questionnaire","volume":"8","author":"Roalfe","year":"2008","journal-title":"BMC Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib54","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1023\/A:1018831127942","article-title":"Quality of life in persons with irritable bowel syndrome. Development and validation of a new measure","volume":"43","author":"Patrick","year":"1998","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2023.11.307_bib55","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1572-0241.2000.01941.x","article-title":"Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire","volume":"95","author":"Drossman","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib56","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/j.1572-0241.2007.01283.x","article-title":"Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment","volume":"102","author":"Drossman","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"583","key":"10.1053\/j.gastro.2023.11.307_bib57","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/11024159850191247","article-title":"Development of a questionnaire to measure quality of life in patients with irritable bowel syndrome","author":"Wong","year":"1998","journal-title":"Eur J Surg Suppl"},{"key":"10.1053\/j.gastro.2023.11.307_bib58","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12955-016-0423-9","article-title":"Irritable bowel syndrome-specific health-related quality of life instrument: development and psychometric evaluation","volume":"14","author":"Lee","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"10.1053\/j.gastro.2023.11.307_bib59","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00384-014-1976-x","article-title":"Development and validation of the irritable bowel syndrome scale under the system of quality of life instruments for chronic diseases QLICD-IBS: combinations of classical test theory and generalizability theory","volume":"29","author":"Lei","year":"2014","journal-title":"Int J Colorectal Dis"},{"key":"10.1053\/j.gastro.2023.11.307_bib60","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1586\/egh.10.19","article-title":"Quality of life measures in irritable bowel syndrome","volume":"4","author":"Wong","year":"2010","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.11.307_bib61","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s11136-016-1421-4","article-title":"A\u00a0systematic review of measurement properties of the instruments measuring health-related quality of life in patients with irritable bowel syndrome","volume":"25","author":"Lee","year":"2016","journal-title":"Qual Life Res"},{"key":"10.1053\/j.gastro.2023.11.307_bib62","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0016-5085(88)90319-8","article-title":"Controlled treatment trials in the irritable bowel syndrome: a critique","volume":"95","author":"Klein","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.11.307_bib63","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/nmo.12151","article-title":"FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?","volume":"25","author":"Corsetti","year":"2013","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2023.11.307_bib64","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ajg.2010.49","article-title":"Rome Foundation endpoints and outcomes conference 2009: optimizing clinical trials in FGIDs","volume":"105","author":"Chang","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib65","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1053\/j.gastro.2009.08.047","article-title":"Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report","volume":"137","author":"Spiegel","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.11.307_bib67","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/MCG.0b013e318189a7f9","article-title":"International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit","volume":"43","author":"Drossman","year":"2009","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib69","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S2468-1253(20)30056-X","article-title":"Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial","volume":"5","author":"Andresen","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.11.307_bib70","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1136\/gutjnl-2021-325821","article-title":"Diet or medication in primary care patients with IBS: the DOMINO study - a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute","volume":"71","author":"Carbone","year":"2022","journal-title":"Gut"},{"issue":"5","key":"10.1053\/j.gastro.2023.11.307_bib71","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14539","article-title":"Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)","volume":"35","author":"Chang","year":"2023","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2023.11.307_bib72","article-title":"A\u00a0randomized controlled long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan","volume":"30","author":"Fukudo","year":"2018","journal-title":"Neurogastroenterol Motil"},{"issue":"5","key":"10.1053\/j.gastro.2023.11.307_bib73","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12876-017-0734-2","article-title":"Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review of randomized controlled trials","volume":"18","author":"Qi","year":"2018","journal-title":"BMC Gastroenterology"},{"key":"10.1053\/j.gastro.2023.11.307_bib74","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jval.2016.11.001","article-title":"Development of the Diary for Irritable Bowel Syndrome Symptoms to assess treatment benefit in clinical trials: Foundational qualitative research","volume":"20","author":"Fehnel","year":"2017","journal-title":"Value Health"},{"key":"10.1053\/j.gastro.2023.11.307_bib75","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jval.2020.01.002","article-title":"Psychometric analysis of the abdominal score from the Diary for Irritable Bowel Syndrome Symptoms\u2013Constipation using phase IIb clinical trial data","volume":"23","author":"Coon","year":"2020","journal-title":"Value Health"},{"key":"10.1053\/j.gastro.2023.11.307_bib76","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.14309\/ajg.0000000000001334","article-title":"Efficacy of linaclotide in reducing abdominal symptoms of bloating, discomfort, and pain: a phase 3B trial using a novel abdominal scoring system","volume":"116","author":"Chang","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib77","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/gutjnl-2020-322519","article-title":"Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care","volume":"70","author":"Black","year":"2021","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2023.11.307_bib78","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cgh.2019.05.037","article-title":"Epidemiological, clinical, and psychological characteristics of individuals with self-reported irritable bowel syndrome based on the Rome IV vs Rome III Criteria","volume":"18","author":"Black","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.11.307_bib79","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/BF02056950","article-title":"A\u00a0constipation scoring system to simplify evaluation and management of constipated patients","volume":"39","author":"Agachan","year":"1996","journal-title":"Dis Colon Rectum"},{"key":"10.1053\/j.gastro.2023.11.307_bib80","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/BF02236639","article-title":"Linear discriminant analysis of symptoms in patients with chronic constipation: validation of a new scoring system (KESS)","volume":"43","author":"Knowles","year":"2000","journal-title":"Dis Colon Rectum"},{"key":"10.1053\/j.gastro.2023.11.307_bib81","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/003655299750025327","article-title":"Psychometric validation of a constipation symptom assessment questionnaire","volume":"34","author":"Frank","year":"1999","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib82","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMoa0800670","article-title":"A\u00a0placebo-controlled trial of prucalopride for severe chronic constipation","volume":"358","author":"Camilleri","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2023.11.307_bib83","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/gut.2008.162404","article-title":"Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives","volume":"58","author":"Tack","year":"2009","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2023.11.307_bib84","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2036.2008.03884.x","article-title":"Clinical trial: the efficacy, impact on quality of life, and safety and\u00a0tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study","volume":"29","author":"Quigley","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.11.307_bib85","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/j.1365-2982.2010.01533.x","article-title":"A\u00a0double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation","volume":"22","author":"Muller-Lissner","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2023.11.307_bib86","doi-asserted-by":"crossref","first-page":"999.e541","DOI":"10.1111\/j.1365-2982.2012.01983.x","article-title":"Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study","volume":"24","author":"Ke","year":"2012","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2023.11.307_bib87","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/nmo.12553","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride","volume":"27","author":"Piessevaux","year":"2015","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2023.11.307_bib88","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/ajg.2015.115","article-title":"A\u00a0randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation","volume":"110","author":"Yiannakou","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib89","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s10620-016-4147-9","article-title":"Efficacy and safety of prucalopride in chronic constipation: an integrated analysis of six randomized, controlled clinical trials","volume":"61","author":"Camilleri","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2023.11.307_bib90","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ajg.2016.611","article-title":"A\u00a0randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation","volume":"112","author":"Miner","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib91","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/1756283X17734697","article-title":"Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation","volume":"10","author":"DeMicco","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib92","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1542-3565(04)00356-8","article-title":"Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial","volume":"2","author":"Johanson","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.11.307_bib93","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3748\/wjg.v13.i5.732","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation","volume":"13","author":"Lin","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib94","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1007\/s10620-009-1068-x","article-title":"Efficacy and safety of lubiprostone in patients with chronic constipation","volume":"55","author":"Barish","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2023.11.307_bib95","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/apt.14349","article-title":"The PAC-SYM questionnaire for chronic constipation: defining the minimal important difference","volume":"46","author":"Yiannakou","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.11.307_bib96","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejpain.2005.03.008","article-title":"Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain","volume":"10","author":"Slappendel","year":"2006","journal-title":"Eur J Pain"},{"key":"10.1053\/j.gastro.2023.11.307_bib97","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1310246","article-title":"Naloxegol for opioid-induced constipation in patients with noncancer pain","volume":"370","author":"Chey","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2023.11.307_bib98","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/2050640615604543","article-title":"Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response","volume":"3","author":"Tack","year":"2015","journal-title":"United European Gastroenterol J"},{"key":"10.1053\/j.gastro.2023.11.307_bib99","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/apt.12899","article-title":"Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation","volume":"40","author":"Webster","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.11.307_bib100","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S2468-1253(17)30105-X","article-title":"Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials","volume":"2","author":"Hale","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.11.307_bib101","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jval.2010.11.003","article-title":"Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms","volume":"14","author":"Iyer","year":"2011","journal-title":"Value Health"},{"key":"10.1053\/j.gastro.2023.11.307_bib102","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1007\/s10620-010-1229-y","article-title":"Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation","volume":"55","author":"Sloots","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2023.11.307_bib103","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00520-014-2435-5","article-title":"Long-term safety and efficacy of oxycodone\/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain","volume":"23","author":"Ahmedzai","year":"2015","journal-title":"Support Care Cancer"},{"issue":"Suppl","key":"10.1053\/j.gastro.2023.11.307_bib104","doi-asserted-by":"crossref","first-page":"A11","DOI":"10.1016\/S0016-5085(98)80043-7","article-title":"Measuring quality-of-life in chronic constipation","volume":"114","author":"Dubois","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.11.307_bib105","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/00365520510012208","article-title":"Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire","volume":"40","author":"Marquis","year":"2005","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib106","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1053\/j.gastro.2009.12.050","article-title":"Efficacy of linaclotide for patients with chronic constipation","volume":"138","author":"Lembo","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.11.307_bib107","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJMoa1010863","article-title":"Two randomized trials of linaclotide for chronic constipation","volume":"365","author":"Lembo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.gastro.2023.11.307_bib108","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1111\/j.1365-2982.2009.01408.x","article-title":"Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation","volume":"22","author":"Dubois","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2023.11.307_bib109","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cgh.2021.05.004","article-title":"Establishing minimal clinically important differences in quality of life measures in opioid-induced constipation","volume":"20","author":"Tack","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.11.307_bib110","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1572-0241.2007.01524.x","article-title":"Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation","volume":"103","author":"Johanson","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib111","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1572-0241.2005.40749.x","article-title":"Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study","volume":"100","author":"Kamm","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib112","first-page":"26","article-title":"An examination of the reliability of reported stool frequency in the diagnosis of idiopathic constipation","volume":"91","author":"Ashraf","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib113","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S2468-1253(18)30123-7","article-title":"Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial","volume":"3","author":"Nakajima","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.11.307_bib114","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13487","article-title":"High-dose linaclotide is effective and safe in patients with chronic constipation: a phase III randomized, double-blind, placebo-controlled study with a long-term open-label extension study in Japan","volume":"31","author":"Fukudo","year":"2019","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2023.11.307_bib115","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/apt.13874","article-title":"An expert consensus definition of failure of a treatment to provide adequate relief (F-PAR) for chronic constipation - an international Delphi survey","volume":"45","author":"Tack","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.11.307_bib116","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.11.307_bib117","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1053\/j.gastro.2016.02.013","article-title":"Multicultural aspects in functional gastrointestinal disorders (FGIDs)","volume":"150","author":"Francisconi","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.11.307_bib118","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/apt.12855","article-title":"The use of pictograms improves symptom evaluation by patients with functional dyspepsia","volume":"40","author":"Tack","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.11.307_bib119","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14364","article-title":"Pictograms are more effective than verbal descriptors in Spanish for bloating and distension","volume":"34","author":"R\u00e1bago","year":"2022","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2023.11.307_bib120","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s10620-018-5343-6","article-title":"Overlap of irritable bowel syndrome and functional dyspepsia in the clinical setting: prevalence and risk factors","volume":"64","author":"von Wulffen","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2023.11.307_bib121","doi-asserted-by":"crossref","first-page":"e945","DOI":"10.1016\/j.cgh.2021.05.042","article-title":"Greater overlap of Rome IV disorders of gut-brain interactions leads to increased disease severity and poorer quality of life","volume":"20","author":"Sperber","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.11.307_bib122","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/ajg.2014.237","article-title":"Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales","volume":"109","author":"Spiegel","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.11.307_bib123","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1007\/s10620-014-3181-8","article-title":"GERD symptoms in the general population: prevalence and severity versus care-seeking patients","volume":"59","author":"Cohen","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2023.11.307_bib124","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13003","article-title":"Gastrointestinal symptom severity in irritable bowel syndrome, inflammatory bowel disease and the general population","volume":"29","author":"Lee","year":"2017","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2023.11.307_bib125","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5056\/jnm17112","article-title":"Lower and upper gastrointestinal symptoms differ between individuals with irritable bowel syndrome with constipation or chronic idiopathic constipation","volume":"24","author":"Shah","year":"2018","journal-title":"J\u00a0Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2023.11.307_bib126","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/ajg.2017.240","article-title":"Evaluation of Gastrointestinal Patient Reported Outcomes Measurement Information System (GI-PROMIS) symptom scales in subjects with inflammatory bowel diseases","volume":"113","author":"Kochar","year":"2018","journal-title":"Am J Gastroenterol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508524001240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508524001240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T21:31:12Z","timestamp":1738013472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508524001240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":123,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0016508524001240"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2023.11.307","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-Reported Outcomes in Disorders of Gut\u2013Brain Interaction","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2023.11.307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the AGA Institute.","name":"copyright","label":"Copyright"}]}}